Introduction/Background TGF-β signaling pathway is one of the most commonly altered cellular signaling pathways in human cancers. Till now limited pharmacogenetic study of TGF- β1gene C509T and T869C polymorphisms has been reported for cervical cancer. So, the aim of the study is to determine whether there is an elevated risk of cervical cancer development with TGF- β1 C509T and T869C polymorphisms in Bangladeshi women.

Methodology A case-control study was conducted with 100 cervical cancer patients and 100 age-sex matched healthy controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.

Results In case of TGF- β1 C509T polymorphism, the frequency distribution of genotypes in controls was 43% CC, 45% CT, 12% TT; in cervical cancer it was found to be 41% CC, 44% CT and 15% TT. No statistically significant differences were observed among heterozygous (OR= 1.083, 95% CI= 0.589–1.993, p>0.05) and mutant homozygous (OR= 1.27, 95% CI= 0.524–3.075, p>0.05) variants compared to normal homozygous variant. In case of T869C polymorphism, the frequency distribution showed the similar trend with 49% TT, 40% TC, 11% CC in controls and 39% TT, 49% TC, 12% CC in patients indicating no association with cervical cancer risk (heterozygous: OR= 1.38, 95% CI= 0.753–2.538, p>0.05; mutant homozygous: OD= 1.46, 95% CI= 0.573–3.730, p>0.05). Moreover, no clinicopathological characteristics i.e. age, dwelling status, menstrual status, parity, contraception of patients was found to be significantly associated with cervical cancer risk. On the contrary, patients with a first-degree relative cancer patient possesses 5.51 folds more risk (p=0.031) of carrying a T allele in C509T variant of the TGF- β1 gene compared to those patients who does not have such relative.

Conclusion This is the first study to identify that Bangladeshi women with C509T and T869C polymorphisms in the TGF- β1 gene are not in risk of developing cervical cancer.

Disclosure Nothing to disclose